Non-virological response to a dolutegravir-containing regimen in a patient harbouring a E157Q-mutated virus in the integrase region.
نویسندگان
چکیده
APHP-Hôpital Necker-Enfants malades, Service de Maladies Infectieuses et Tropicales, Centre d’Infectiologie Necker-Pasteur, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; IHU Imagine, Paris, France; AP-HP, Groupe Hospitalier Xavier Bichat-Claude Bernard, UF 301 Laboratoire de PharmacoToxicologie, F-75018 Paris, France; INSERM, IAME, UMR 1137, Université Paris Diderot, Sorbonne Paris Cité, Paris, France; Laboratoire de Biologie et Pharmacologie Appliquée, Centre National de la Recherche Scientifique UMR8113, Cachan, France; APHP-Hôpital Necker-Enfants malades, Service de Néphrologie et Transplantation Adulte, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, RTRS Centaure, Labex Transplantex, Paris, France; APHP-Hôpital Necker-Enfants malades, Service de Virologie, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, EA7327 Paris, France
منابع مشابه
Resistance to HIV Integrase Inhibitors: About R263K and E157Q Mutations
The use of integrase inhibitors (INI) is increasing in antiretroviral therapies (ART) and INI are not all equal regarding genetic barrier to resistance. The aim of this manuscript was to review main in vivo and in vitro knowledge about two particular integrase resistance-associated mutations: R263K and E157Q. The R263K mutation was the first mutation rarely found selected at time of virological...
متن کاملNew dolutegravir resistance pattern identified in a patient failing antiretroviral therapy
INTRODUCTION The most recently approved antiretroviral, the integrase inhibitor dolutegravir (DTG), is described to be a very potent drug with a unique resistance profile, but a certain degree of cross-resistance to RAL or EVG induced drug resistance, which is mediated mainly by integrase mutations at positions 140 and 148. The impact of a single N155H mutation to DTG resistance is described to...
متن کاملUse of dolutegravir in two INI-experienced patients with multiclass resistance resulted in excellent virological and immunological responses
INTRODUCTION Dolutegravir is a second generation integrase inhibitor with a proposed high genetic barrier to resistance. However, in clinical trials, decreased virological response was seen in a subset of patients with prior exposure to raltegravir and multiple integrase resistance mutations. METHODS We describe two cases of HIV subtype B-infected patients starting dolutegravir after previous...
متن کاملHigh frequency of dolutegravir resistance in patients failing a raltegravir-containing salvage regimen.
OBJECTIVES Dolutegravir is a second-generation integrase strand transfer inhibitor (InSTI) that has been recently approved by the FDA to treat antiretroviral therapy-naive as well as treatment-experienced HIV-infected individuals, including those already exposed to the first-generation InSTI. Despite having a different mutational profile, some cross-resistance mutations may influence its suscep...
متن کاملResistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors.
OBJECTIVE Among 1222 antiretroviral-naive patients who received dolutegravir (DTG) as part of first-line therapy, none has developed resistance against this compound after 48-96 weeks of follow-up. Moreover, only four occurrences of virological failure with resistance mutations have been documented in previously drug-experienced patients who received DTG as a first time integrase inhibitor as a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- The Journal of antimicrobial chemotherapy
دوره 70 6 شماره
صفحات -
تاریخ انتشار 2015